FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Genentech receives FDA acceptance for Gazyva sBLA
Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application for Gazyva ...
PMLiVE15h
Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke
Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...
Genentech gets FDA acceptance for its Lupus treatment's license application
Genentech, a Roche Group company(OTCQX:RHHBY) said on Wednesday that the U.S. FDA accepted the company’s supplemental ...
Healio13h
Subcutaneous adjuvant regimen for breast cancer reduces ‘time toxicity’ of treatment
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...
Pharmabiz51m
US FDA accepts Roche’s Gazyva/Gazyvaro sBLA for the treatment of lupus nephritis
US FDA accepts Roche’s Gazyva/Gazyvaro sBLA for the treatment of lupus nephritis: Basel Thursday, March 6, 2025, 09:00 Hrs [IST] Roche announced that the US Food and Drug Admini ...
Daily22h
FDA Approves Tenecteplase as First Stroke Drug in Nearly 30 Years
The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...
manilatimes22h
FDA accepts supplemental Biologics License Application for Roche's Gazyva/Gazyvaro for the treatment of lupus nephritis
"In people with lupus nephritis, Gazyva/Gazyvaro demonstrated a complete renal response benefit, a meaningful clinical ...
Lupus Foundation of America14h
FDA Accepts Supplemental Biologics License Application for Gayzva for Treatment of Lupus Nephritis
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s Supplemental Biologics License Application (sBLA) for ...
Healio14h
Response to peanut patch treatment increases through 60 months
Percentages of children with peanut allergy who responded to treatment with the VP250 VIASKIN Peanut patch from DBV Technologies increased from 12 months through 60 months, according to an abstract ...
dermatologyadvisor13h
Omalizumab Superior to Oral Immunotherapy in Multifood Allergy
Omalizumab superior to oral immunotherapy for multifood allergy, and most patients consume allergy-triggering foods after gaining tolerance.
Obesity Care Week 2025 Calls for Action on CMS Proposed Rule to Expand Access to Obesity Treatment
As Obesity Care Week (OCW) 2025 continues, supporters nationwide are rallying behind the Centers for Medicare & Medicaid Services (CMS) Proposed Rule, which could expand Medicare Part D coverage to ...